anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats but not in studies involving hamsters.

Metronidazole has shown evidence of mutagenic activity in several in vitro bacterial assay systems. In addition, a dose-response increase in the frequency of micronuclei was observed in mice after intraperitoneal injections and an increase in chromosome aberrations have been reported in patients with Crohn's disease who were treated with 200-1200 mg/day of metronidazole for 1 to 24 months. However, no excess chromosomal aberrations in circulating human lymphocytes have been observed in patients treated for 8 months.

Pregnancy: Teratogenic effects: Pregnancy category B: There has been no experience to date with the use of metronidazole topical gel USP, 0.75%, in pregnant patients. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral metronidazole in rats or mice. However, because animal reproduction studies are not always predictive of human response and since oral metronidazole has been shown to be a carcinogen in some rodents, this drug should be used during pregnancy only if clearly needed.
This retrospective study describes the surgical outcomes of our first 20 transgender women to undergo feminization thyroid laryngochondroplasty (FLC) by a direct transvestibular FLC (DTV-FLC) approach from December 2019 to October 2023. The medical records of all patients were retrieved and reviewed. Data on the operative, postoperative, and follow-up courses, complications, and functional and cosmetic outcomes were retrieved. The cosmetic results were evaluated by four independent facial plastic surgeons. Thirteen patients underwent DTV-FLC combined with genioplasty or genioplasty with mandibular angle reduction and seven underwent isolated DTV-FLC. DTV-FLC was feasible in all planned cases. Complications (skin flap perforation, thyroid cartilage fracture, mental hypoesthesia, hematoma, dehiscence of the vestibular incision, vestibular scar adhesions, and anemia) were minor and resolved spontaneously. The preoperative grade of thyroid cartilage protrusion was 1.9 ± 0.9 on a scale from 1 to 3. The postoperative cosmetic results of 18 patients were judged as having improved (a score of 2.1 ± 0.8 on a scale from -1 to 3). Eighteen patients were satisfied with the cosmetic result, one was dissatisfied (the revision surgery patient), and one was lost to follow-up. In conclusion, DTV-FTLC is a valid surgical approach for FLC, yielding high patient satisfaction and good cosmetic results.
Disorders and diseases in human and animal digestive systems, for example diarrhoea, ulcerative disorders and carcinomas, are a serious, economically important problem worldwide. It was possible to show that immunological mechanisms exhibit a protective effect in the gastrointestinal tract of animals and humans. Antigens contained in the food induce the said protective mechanisms if the body has previously been sensitised to this antigen. The use of antigenic substances in the prophylaxis and therapy of ulcerative disorders in humans is preferred. The antigenic substances according to the invention are furthermore particularly highly suitable in the raising of young cattle, which are subjected to a change of food in the first weeks of life. <IMAGE>
The pain associated with chest tube removal (CTR) is one of the significant complications of cardiac surgery. The management of this pain is recognized as a vital component of nursing care. The application of distraction techniques using virtual reality (VR) is an effective and straightforward non-pharmacological approach to alleviate pain. This study aimed to determine the impact of VR technology on the management of pain caused by CTR following coronary artery bypass grafting (CABG). This randomized clinical trial was conducted on 70 patients undergoing CABG at Imam Reza and Qaem hospitals in Mashhad, Iran, in 2020. The patients were randomly divided into two groups of 35. For the intervention group, a 360-degree video was played using VR glasses 5 min before the CTR procedure. The pain intensity was measured before, immediately after, and 15 min after CTR, using the Visual Analogue Scale. Also, the Depression Anxiety and Stress Scale-21 (DASS-21), and the Rhoten Fatigue Scale (RFS) were used to evaluate intervention and control groups before the CTR procedure. The collected data was analyzed using statistical tests, such as Chi-square, independent t-test, and Mann-Whitney test. The patients were homogeneous in terms of stress, anxiety, and fatigue levels before CTR, and they did not show any significant differences (P > 0.05). The average pain intensity score of patients in the intervention group significantly decreased immediately and 15 min after CTR, compared to the control group (P < 0.001). Given the positive impact of VR distraction on the severity of pain associated with CTR in patients undergoing CABG, this technique can serve as an effective, accessible, and cost-efficient non-pharmacological approach for managing pain in these patients.Trial registration: This study was registered in the Iranian Registry of Clinical Trials (code: IRCT20190708044147N1; approval date, 08/26/2019).
DNA coding for the polypeptide inhibin has been identified and characterised and this, as well as methods used in identification thereof, form part of the invention. Also claimed are probes useful in identifying such DNA. Recombinant DNA including cloning vectors are claimed which include DNA coding for all, part, analogues, homologues or precursors of inhibin as well as a protein having similiar immunological or biological activity, as well as cells transformed with the vectors and capable of expressing a polypeptide which includes all or part, analogues, homologues or precursors of inhibin or similar polypeptides. Methods for producing the vectors and transformed cells are also part of the invention. Inhibin or part, analogues, homologues or precursors thereof when produced by such recombinant techniques are also claimed, as well as pharmaceutical compositions thereof. A  further aspect of the invention resides in fragments of inhibin produced by recombinant techniques such as the method disclosed as well as synthetic peptides having sequences corresponding or similar to such fragments. Pharmaceutical compositions containing such fragments are also claimed. In a further aspect of the invention uses of the recombinant and synthetic polypeptides are claimed which reside primarily in affecting gonadal function in vertebrates. Antibodies to these polypeptides are also disclosed and these are also useful in affecting gonadal function in vertebrates and thus form part of the invention.
CB-03-01 (cortexolone 17α-propionate) Cream, 1%, applied twice daily to whole face (about 1 gram) and affected areas of trunk (if applicable) for up to an additional 9 months. Over the course of the study, treatment on the face and/or trunk may be discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area.
The dynamic of plant-parasitic nematode populations in soil is closely related to soil microorganisms. Fungi from Heterodera zeae cysts were isolated to explore the phenomenon of decline in the H. zeae population in the soil. Phylogenetic study of partial ITS, BenA, CaM, and RPB2 gene sequences, in addition to morphological investigations, was utilized to identify a nematode-destroying fungus. The nematicidal activity of a novel strain GX1 against H. zeae was assessed in vitro and in the greenhouse. Our findings revealed that strain GX1 is a new species of Talaromyces, named Talaromyces cystophila. It has a strong parasitic and lethal effect on H. zeae cysts, with 91.11% parasitism on cysts at 3 days after treatment. The contents of second-stage juveniles (J2s) and eggs inside the cysts were degraded and formed dense vacuoles, and the damaged eggs could not hatch normally. The spore suspension exhibited high nematophagous activity against nematodes, and fermentation filtrate exhibited marked inhibition of egg hatching and nematicidal activities on J2s. The hatching inhibition rates of eggs exposed to 1 × 108 CFU/ml spore suspensions or 20% 1-week fermentation filtrate (1-WF) for 15 days were 98.56 and 100%, respectively. The mortality of J2s exposed to 1 × 108 CFU/ml spore suspension reached 100% at 24 h; exposure to 50% 2-WF was 98.65 and 100% at 24 and 48 h, respectively. Greenhouse experiments revealed that the spore suspension and fermentation broth considerably decreased H. zeae reproduction by 56.17 to 78.76%. T. cystophila is a potential biocontrol strain with nematophagous and nematicidal activity that deserves attention and application.
Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of CONSOLIDATION therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.
Coffee consumption has been associated with several risk factors leading to cardiovascular diseases (CVDs), including hyperhomocysteinemia and hyperlipidemia. Frequent coffee consumption has beneficial effects in reducing the risk of diabetes mellitus (DM) type 2, obesity, liver disease, CVDs, some types of cancer, Parkinson's disease, and Alzheimer's disease. Controversies concerning coffee consumption benefits and risks in regards for CVDs were mentioned in many studies. Folic acid and vitamin B12 are necessary vitamins in homocysteine metabolism which is a risk factor for atherosclerosis. Leptin, is a hormone linked to obesity and it could be related to atherosclerosis.

The combined effect of coffee consumption and body weight on the levels of leptin, folic aid, and vitamin B12 is not well studied. In our study, we will study the effect of coffee consumption in males with different body mass indices to see the effect of several important parameters such as leptin, Folic acid, and vitamin B12.
Immunocompromised patients account for an increasing proportion of the typical intensive care unit (ICU) case-mix. Because of the increased availability of new drugs for cancer and auto-immune diseases, and improvement in the care of the most severely immunocompromised ICU patients (including those with hematologic malignancies), critically ill immunocompromised patients form a highly heterogeneous patient population. Furthermore, a large number of ICU patients with no apparent immunosuppression also harbor underlying conditions altering their immune response, or develop ICU-acquired immune deficiencies as a result of sepsis, trauma or major surgery. While infections are associated with significant morbidity and mortality in immunocompromised critically ill patients, little specific data are available on the incidence, microbiology, management and outcomes of ICU-acquired infections in this population. As a result, immunocompromised patients are usually excluded from trials and guidelines on the management of ICU-acquired infections. The most common ICU-acquired infections in immunocompromised patients are ventilator-associated lower respiratory tract infections (which include ventilator-associated pneumonia and tracheobronchitis) and bloodstream infections. Recently, several large observational studies have shed light on some of the epidemiological specificities of these infections-as well as on the dynamics of colonization and infection with multidrug-resistant bacteria-in these patients, and these will be discussed in this review. Immunocompromised patients are also at higher risk than non-immunocompromised hosts of fungal and viral infections, and the diagnostic and therapeutic management of these infections will be covered. Finally, we will suggest some important areas of future investigation.
Sequentially enrolled symptomatic patients will have a nasal swab collected for high-sensitive SARS-CoV-2 RT-PCR testing as comparator and self collect a nasal swab for CoviDx™ Covid-19 Antigen self-testing. Order of tests will be performed following a randomization scheme.
Patients receive gallium Ga 68-labeled PSMA-11 IV. 50-100 minutes after injection, patients then undergo a PET/CT scan or PET/MRI scan over 60 minutes.
Eligible 16 subjects will be randomized in Cohort A2 (n=16; 12 active: 4 Placebo) and will receive the investigational product (RHN-001) or placebo on Day 2 (dosing day) within 30 minutes after a standard breakfast. All subjects will undergo a 24-hour PK study during their stay at the clinical trial site.
Risk Summary

Based on findings in animal studies and mechanism of action, TRELSTAR can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. Expected hormonal changes that occur with TRELSTAR treatment increase the risk for pregnancy loss. In animal developmental and reproductive toxicology studies, daily administration of triptorelin to pregnant rats during the period of organogenesis caused maternal toxicity and embryo-fetal toxicities, including loss of pregnancy, at doses as low as 0.2, 0.8, and 8 times the estimated human daily dose based on body surface area. Advise pregnant patients and females of reproductive potential of the potential risk to the fetus. 

Data

Animal Data

Studies in pregnant rats administered triptorelin at doses of 2, 10, and 100 mcg/kg/day (approximately equivalent to 0.2, 0.8, and 8 times the estimated human daily dose based on body surface area) during the period of organogenesis demonstrated maternal toxicity and embryo-fetal toxicities. Embryo-fetal toxicities consisted of pre-implantation loss, increased resorption, and reduced mean number of viable fetuses at the high dose. Teratogenic effects were not observed in viable fetuses in rats or mice. Doses administered to mice were 2, 20, and 200 mcg/kg/day (approximately equivalent to 0.1, 0.7, and 7 times the estimated human daily dose based on body surface area).
PURPOSE:To store the picture information without losing various additional information on digital pictures by transferring the contents of the stored additional information to the processes of following stages by means of an identifier. CONSTITUTION:The identifier corresponding to the contents of the additional information is supplied to an input identifier register 11 when the contents of the necessary additional information are obtained from a picture information storing part 15. Then the identifier of the register 11 is compared with the identifier of an identifier register 18 through a comparator 12. If no coincidence is obtained between both identifiers, a pointer control register 13 reads the contents of a key information length register 17 with an instruction given from the comparator 12. Then the instruction is given to a pointer register 14 to extract the next key information out of the part 15. The identifier of the extracted key information is held by the register 18 and compared again with the input identifier through the comparator 12. This operation is repeated until the coincidence is obtained between identifiers. When the coincidence is obtained, the contents of this coincidence are extracted to an additional information contents register 19 for output.
PURPOSE:To obtain the title liposome with high hemoglobin content, especially useful as an artificial oxygen carrier by including a hemoglobin solution with the pH value adjusted to a specified level in a mixed lipid containing an aliphatic compound having specific substituent and phospholipid. CONSTITUTION:A hemoglobin solution with the pH value adjusted to 7.0-7.8 is included in a mixed lipid containing (A) an aliphatic compound having carboxylic or phosphoric acid group (e.g. fatty acid, phosphatidic acid, ceramide phosphoric acid) and (B) a phospholipid as a liposome film-forming skeletal substance and, where appropriate, (C) a film-stabilizing substance (e.g. cholesterol). The present pH-adjusted hemoglobin, compared to pH-unadjusted ones, will inhibit methemoglobin formation, therefore, can be improved in its stability along with extended storage period. And because of the use of the composite lipid, the delta-potential will get controllable like the case with erythrocyte film; thus the present hemoglobin can be imparted with biocompatibility and improved in the stability of the particles in vivo and during storage.
Treatment with glucocorticosteroids, including budesonide rectal foam, is associated with a suppression of endogenous cortisol concentrations and an impairment of the hypothalamic-pituitary-adrenal (HPA) axis function. These effects were measured by determination of plasma cortisol concentrations and responses to adrenocorticotropin challenge (i.e., ACTH stimulation test) in 2 placebo-controlled, 6-week trials in patients with active disease [see Clinical Studies (14)]. These trials enrolled subjects with post-ACTH stimulation cortisol levels of >18 mcg/dL at baseline. Subjects received budesonide rectal foam 2 mg or a placebo twice daily for 2 weeks followed by once daily for 4 weeks. Normal morning serum cortisol levels >5 mcg/dL were maintained in 85% and 84% of budesonide rectal foam treated subjects during Weeks 1 and 2 (twice daily treatment) and 93% and 94% during Weeks 4 and 6 (once daily treatment), respectively (see Table 3).

At baseline (predose), 84% of subjects in the budesonide rectal foam group had a normal response to the ACTH challenge and at Week 6, 63% of subjects had a normal response to the ACTH challenge; in the placebo group, these values were 86% and 76%, respectively (see Table 3). ACTH stimulation test was not performed routinely during the twice daily treatment period (Weeks 1 and 2).

Table 3: Proportion of Subjects with Normal Endogenous Cortisol Levels (>5 mcg/dL) During the Study and Proportion of Subjects with Normal Response to ACTH Challenge

aThe normal response to ACTH challenge included 3 criteria, as defined in the cosyntropin label: 1) morning cortisol level >5 mcg/dL; 2) increase in cortisol level by ≥7 mcg/dL above the morning (pre-challenge) level following ACTH challenge; and cortisol level of >18 mcg/dL following ACTH challenge.

bDenominator includes 20 subjects in the budesonide rectal foam arm and 2 subjects in the placebo arm who discontinued prior to Week 6 due to adverse events related to low cortisol or abnormal response to ACTH challenge.
FIELD: biotechnology, immunology. SUBSTANCE: hybridoma is prepared by immunization of hamster with a rat purified α d  and rat transfected α d  CHO cells followed by fusion of splenocytes with NS-1 myeloma cells and screening the target cells. Hybridoma produces monoclonal antibody exhibiting reaction with α-subunit of rat integrin α d . Invention can be used in immunohistochemical analysis for assay of localization of α d . Invention ensures to determine localization of α d  in tissues. EFFECT: improved method of hybridoma preparing, valuable properties. 2 cl, 4 dwg, 1 tbl
This arm includes participants who have completed study EFC16293 or study EFC16295, participants who have completed Arm B or Arm C of this study (LTS16294) and roll over into Arm A, and participants who have completed any other potential BIVV001 study. Participants in this arm will continue receiving BIVV001 prophylaxis treatment once weekly (QW) for a total of 100 exposure days (EDs) cumulative from the parent study and this study. Participants will have the opportunity to continue in this study for up to 4 years, unless BIVV001 is commercially available in their applicable participating country.
Children with rheumatic disease who were diagnosed with chronic rheumatic disease, diagnosed at least 6 months ago, whose medical treatment was stable, and who volunteered to participate in the study will be included. Within the scope of the project, participants' demographic data, health parameters, physical fitness, functional capacity, fatigue level, exercise behavior, system availability and satisfaction will be evaluated. All assessments and training on smartwatches and mobile and web-based physical activity tracking applications will be held at Department of Pediatric Rheumatology, Istanbul Faculty of Medicine, Istanbul University.
The invention discloses a method for preparing antibacterial agent carrying zinc and metasilicate and its usage. The method comprises the followinf steps :( 1) montmorillonite sodiuming; (2) making montmorillonite load chitose; (3) loading zinc; (4) drying filter cake and disintegrating. The product can be used as feed additive for poultry, aquatic creature, sheep and cow, and it possesses strong antibiotic action. It is hard for bacteria to generate drug tolerance. The product can effectively inhibit the propagation of enteric pathogenic bacteria, which is good for secretory of digestive enzyme and digestion of feed. The product can increase animal survival rate, reduce loose bowel movement and increase production capacity, it can also replace antibiotics and antibacterial drugs, and there is no antibiotics residue in animal product.
The present invention provides a novel cDNA sequence of an apoptosis promoting ligand (APO), a coded amino acid sequence thereof, a function thereof for promoting apoptosis and an application thereof, and provides a preparation method and an application for an antibody thereof. The cDNA sequence is formed from 381 basic groups, and the length of the amino acid sequence is the length of 126 amino acids. The protein of the cDNA sequence, which is expressed in colibacillus, has obvious inhibiting effects on bacillus growth, and the protein of the cDNA sequence, which is expressed in the mammalian cell, can cause cell apoptosis. Thus, a polypeptide molecule encoded by the cDNA sequence can be used as an inducting agent for promoting tumor cell apoptosis clinically to treat tumors, and performs effects on differentiation induction and treatment for tumors. The present invention determines epitope by analyzing the amino acid sequence to synthesize a polypeptide for preparing a monoclonal antibody, and a protein stamp technique indicates that the monoclonal antibody can specifically recognize the novel apoptosis promoting ligand (APO). Thus, the monoclonal antibody can be used for preventing normal cells from apoptosis so as to protect the normal tissue and avoid wrong apoptosis.